$995 Million is the total value of HealthCor Management, L.P.'s 58 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | PYXIS ONCOLOGY INC | $0 | – | -217,457 | -100.0% | -0.06% | – | |
| PCRX | Exit | PACIRA BIOSCIENCES INC | $0 | – | -13,930 | -100.0% | -0.07% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLC | $0 | – | -9,170 | -100.0% | -0.10% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -23,480 | -100.0% | -0.15% | – |
| STXS | Exit | STEREOTAXIS INC | $0 | – | -821,850 | -100.0% | -0.20% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -140,630 | -100.0% | -0.25% | – |
| CANO | Exit | CANO HEALTH INC | $0 | – | -711,970 | -100.0% | -0.30% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -9,570 | -100.0% | -0.45% | – |
| MRVI | Exit | MARAVAI LIFESCIENCES HLDGS I | $0 | – | -200,000 | -100.0% | -0.47% | – |
| SYK | Exit | STRYKER CORPORATION | $0 | – | -43,760 | -100.0% | -0.78% | – |
| HCA | Exit | HCA HEALTHCARE INC | $0 | – | -48,890 | -100.0% | -0.82% | – |
| PFE | Exit | PFIZER INC | $0 | – | -242,880 | -100.0% | -0.84% | – |
| RACB | Exit | RESEARCH ALLIANCE CORP II | $0 | – | -1,324,800 | -100.0% | -0.86% | – |
| CAH | Exit | CARDINAL HEALTH INC | $0 | – | -317,280 | -100.0% | -1.20% | – |
| WOOF | Exit | PETCO HEALTH & WELLNESS CO I | $0 | – | -1,215,000 | -100.0% | -1.59% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -108,890 | -100.0% | -1.76% | – |
| CVS | Exit | CVS HEALTH CORP | $0 | – | -286,600 | -100.0% | -1.94% | – |
| TFX | Exit | TELEFLEX INCORPORATED | $0 | – | -99,150 | -100.0% | -2.35% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -254,160 | -100.0% | -2.75% | – |
| NVST | Exit | ENVISTA HOLDINGS CORPORATION | $0 | – | -914,490 | -100.0% | -2.97% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -600,000 | -100.0% | -3.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
| ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
| DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
| NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
| UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
| VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
| HUMANA INC | 22 | Q3 2022 | 6.6% |
| BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
| BIOGEN INC | 21 | Q3 2022 | 8.5% |
| LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
| Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
| Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
| Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
| ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-05-26 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-26 |
| 4 | 2023-04-04 |
| 4 | 2023-04-04 |
| SC 13D/A | 2023-04-03 |
| 13F-HR | 2023-02-15 |
| SC 13G/A | 2023-02-14 |
| 4 | 2023-01-04 |
| 4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.